This study is a prospective, randomized, open-label study.~The CHB subjects who are cirrhosis will be randomized to two groups.~The subjects who go into group A will be treated by nucleotide analogue (NA) combination with peginterferon alfa-2a,180μg/week for 48 weeks.~The subjects who go into group B will be treated by nucleotide analogue (NA) only for 48 weeks.
The CHB subjects who are cirrhosis, will be randomized to two groups.~The subjects who go into group A will be treated by nucleotide analogue (NA) combination with peginterferon alfa-2a,180μg/week for 48 weeks.~The subjects who go into group B will be treated by nucleotide analogue (NA) only for 48 weeks.